DBV Technologies S.A.
DBVT
NASDAQ
IPO2014
about DBVT
DBV Technologies is a biopharmaceutical company specializing in innovative treatments for allergies, with its lead product designed to address conditions such as allergic asthma and seasonal allergies through allergen-specific immunotherapy.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $17.50 | $18.28 | $17.50 | $734.04M | 867.41K |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.24 | n/a | 1430.26 | -1235.65% | -1195.53% | 0% |